BlackRock
VRDN icon

BlackRock’s Viridian Therapeutics VRDN Stock Holding History

BlackRock’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$157M Buy
8,551,488
+720,013
+9% +$11.6M ﹤0.01% 1945
2026
Q1 		$153M Buy
7,831,475
+1,399,552
+22% +$41.6M ﹤0.01% 1833
2025
Q4 		$200M Buy
6,431,923
+1,003,402
+18% +$27.5M ﹤0.01% 1688
2025
Q3 		$117M Sell
5,428,521
-92,514
-2% -$1.67M ﹤0.01% 2006
2025
Q2 		$77.2M Sell
5,521,035
-187,075
-3% -$2.54M ﹤0.01% 2217
2025
Q1 		$76.9M Sell
5,708,110
-50,467
-0.9% -$860K ﹤0.01% 2150
2024
Q4 		$110M Buy
5,758,577
+954,571
+20% +$20.8M ﹤0.01% 2023
2024
Q3 		$109M Buy
4,804,006
+30,384
+0.6% +$497K ﹤0.01% 2033
2024
Q2 		$62.1M Buy
4,773,622
+960,992
+25% +$13.3M ﹤0.01% 2289
2024
Q1 		$66.8M Buy
3,812,630
+386,180
+11% +$7.49M ﹤0.01% 2285
2023
Q4 		$74.6M Buy
3,426,450
+433,387
+14% +$6.84M ﹤0.01% 2257
2023
Q3 		$45.9M Sell
2,993,063
-123,072
-4% -$2.35M ﹤0.01% 2439
2023
Q2 		$74.1M Buy
3,116,135
+342,749
+12% +$8.79M ﹤0.01% 2247
2023
Q1 		$70.6M Buy
2,773,386
+11,830
+0.4% +$379K ﹤0.01% 2231
2022
Q4 		$80.7M Buy
2,761,556
+779,494
+39% +$18M ﹤0.01% 2151
2022
Q3 		$40.7M Buy
1,982,062
+559,238
+39% +$10.1M ﹤0.01% 2604
2022
Q2 		$16.5M Buy
1,422,824
+1,270,049
+831% +$17.1M ﹤0.01% 3191
2022
Q1 		$2.83M Sell
152,775
-351
-0.2% -$6.74K ﹤0.01% 4246
2021
Q4 		$3.03M Buy
153,126
+102,285
+201% +$1.91M ﹤0.01% 4225
2021
Q3 		$836K Buy
50,841
+589
+1% +$8.64K ﹤0.01% 4605
2021
Q2 		$919K Buy
50,252
+19,365
+63% +$331K ﹤0.01% 4542
2021
Q1 		$516K Hold
30,887
– – ﹤0.01% 4606
2020
Q4 		$508K Sell
30,887
-5,758
-16% -$86.8K ﹤0.01% 4346
2020
Q3 		$426K Hold
36,645
– – ﹤0.01% 4292
2020
Q2 		$610K Buy
36,645
+7,295
+25% +$82.8K ﹤0.01% 4165
2020
Q1 		$196K Buy
29,350
+1,673
+6% +$19.5K ﹤0.01% 4234
2019
Q4 		$199K Sell
27,677
-52
-0.2% -$533 ﹤0.01% 4319
2019
Q3 		$304K Hold
27,729
– – ﹤0.01% 4258
2019
Q2 		$853K Sell
27,729
-66,165
-70% -$2.66M ﹤0.01% 4052
2019
Q1 		$3.93M Sell
93,894
-3,431
-4% -$155K ﹤0.01% 3499
2018
Q4 		$4.42M Buy
97,325
+3,208
+3% +$186K ﹤0.01% 3433
2018
Q3 		$7.88M Buy
94,117
+1,285
+1% +$121K ﹤0.01% 3341
2018
Q2 		$8.93M Buy
92,832
+38,877
+72% +$4.11M ﹤0.01% 3290
2018
Q1 		$5.67M Buy
53,955
+15,627
+41% +$1.7M ﹤0.01% 3375
2017
Q4 		$6M Buy
38,328
+1,714
+5% +$218K ﹤0.01% 3365
2017
Q3 		$5.03M Buy
36,614
+2,225
+6% +$374K ﹤0.01% 3463
2017
Q2 		$6.67M Buy
34,389
+34,381
+429,763% +$5.8M ﹤0.01% 3373
2017
Q1 		$1K Buy
+8
New +$1.38K ﹤0.01% 4967

Other funds holding VRDN

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

BlackRock's VRDN Position: Q2 2026 in Review

BlackRock increased its Viridian Therapeutics (VRDN) stake by 9.2% in Q2 2026, buying an estimated $11.6M and bringing the position to 8,551,488 shares worth $157M. The position accounts for ﹤0.01% of the portfolio, ranked #1945.

BlackRock first reported a position in VRDN in Q1 2017 and has held it in 38 quarters since. The position peaked at $200M in Q4 2025. 65 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • BlackRock held 8,551,488 shares of Viridian Therapeutics worth $157M as of Q2 2026.
  • BlackRock bought 720,013 Viridian Therapeutics shares in Q2 2026, an estimated $11.6M.
  • Viridian Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1945 holding.
  • BlackRock first reported a position in Viridian Therapeutics in Q1 2017 and has held it in 38 quarters since.
  • BlackRock's Viridian Therapeutics position peaked at $200M in Q4 2025.
  • 65 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.